Personalized Search
Displaying 801 - 820 of 1079
The U.S. Food and Drug Administration (FDA) approved
fludarabine
fludarabine:
The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in combination with other medicines for treating bone marrow failure.
for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in…
Drug last updated
.
Node ID (debugging only): 929
It is known as a hematopoietic
growth factor
growth factor:
A substance made by the body that stimulates the bone marrow to produce blood cells. Some growth factors are man-made in the laboratory and used for treating low blood counts. These include red blood cell growth factors called erythropoietin (EPO) and darbepoetin, and white blood cell growth…
or colony stimulating factorand is…
Drug last updated
.
Node ID (debugging only): 928
Epoetin alfa
Epoetin alfa:
Epoetin alfa can help improve red blood cell counts in bone marrow failure disease patients whose natural erythropoietin levels are low. It is given by injection under the skin (subcutaneous) or in the vein (intravenous). Epoetin alfa is approved by the U.S. Food and Drug Administration (FDA) for…
can help improve
red blood cell
red blood cell:
The…
Drug last updated
.
Node ID (debugging only): 927
What are the possible side effects of eltrombopag (Promacta)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using
eltrombopag
eltrombopag:
What are the possible side effects of eltrombopag (Promacta)?
Get emergency medical help if you have any of these signs of an…
Drug last updated
.
Node ID (debugging only): 914
Deferoxamine
Deferoxamine:
Deferoxamine is an iron-binding agent that belongs to a class of drugs known as heavy metal antagonists. It works by helping the kidneys and gallbladder get rid of the extra iron.
is an iron-binding agent that belongs to a class of drugs known as heavy metal antagonists. It works by helping the kidneys and gallbladder get rid of the extra iron.
Drug last updated
.
Node ID (debugging only): 965
Eculizumab
Eculizumab:
Eculizumab (Soliris ®) is given as an IV into a vein at the doctor’s office or at a special center. The procedure usually takes about 35 minutes. You will probably get an IV once a week for the first 4 weeks. Starting in the 5th week, you will get a slightly higher dose of Soliris every 2 weeks.
…
(Soliris ®) is given as an IV into a vein at the doctor’s office…
Drug last updated
.
Node ID (debugging only): 926
INQOVI® for adult patients with MDS or CMML who are intermediate-1, intermediate-2, and high-risk IPSS groups. It is a prescribed oral tablet combination of decitabine and cedazurine approved by the FDA for adult patients with myelodysplastic syndromes (MDS) and patients with chronic myelomonocytic leukemia (CMML) including:
previously treated and…
Drug last updated
.
Node ID (debugging only): 956
It comes in a tablet form which is dissolved in juice or water and taken by mouth. Iron build-up can occur in patients who get a lot of
red blood cell
red blood cell:
The most numerous type of blood cell in healthy people. Red blood cells contain hemoglobin, a protein that picks up oxygen in the lungs and brings it to cells in all parts of the body. Also called erythrocyte, RBC.…
Drug last updated
.
Node ID (debugging only): 924
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely.
Decitabine
Decitabine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like…
Drug last updated
.
Node ID (debugging only): 923
It is in a class of medicines called erythropoiesis-stimulating agents (ESAs).
Darbepoetin alfa
Darbepoetin alfa:
It is in a class of medicines called erythropoiesis-stimulating agents (ESAs). Darbepoetin alfa can help improve red blood cell counts in bone marrow failure patients whose natural erythropoietin levels are low. It is given by injection under the skin (subcutaneous) or in…
Drug last updated
.
Node ID (debugging only): 922
Cyclosporine
Cyclosporine:
Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and some other forms of bone marrow failure.
is used along with
antithymocyte globulin
antithymocyte globulin:
ATG is an immunosuppressant, a drug that lowers the body's immune response. It is typically used with cyclosporine as the…
Drug last updated
.
Node ID (debugging only): 920
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely.
Azacitidine
Azacitidine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts…
Drug last updated
.
Node ID (debugging only): 919
Alemtuzumab
Alemtuzumab:
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada. It is also used in some conditioning regimens for…
is a drug used in the treatment of chronic lymphocytic…
Drug last updated
.
Node ID (debugging only): 916
Cyclophosphamide
Cyclophosphamide:
Cyclophosphamide is in a class of medications called alkylating agents. When used to treat cancer, it works by slowing or stopping the growth of cancer cells in your body. When cyclophosphamide is used to treat bone marrow failure, it works by suppressing your body's immune system.
is in a class of medications called alkylating agents. When used to…
Drug last updated
.
Node ID (debugging only): 915
Romiplostim
Romiplostim:
Romiplostim is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets. Romiplostim injection is used to increase the number of platelets enough to lower the risk of bleeding, but it is not used to increase the…
is in a class of medications called thrombopoietin receptor…
Drug last updated
.
Node ID (debugging only): 969
Learn about
biosimilars
biosimilars:
What is a Biosimilar?
A biosimilar is a type of biologic medication. The term “biosimilar” means that the medication is highly similar to the already approved brand name biologic (“originator” medication). Biosimilars are not generic versions of the original biologic.
Difference Between…
, biosimilar medications, and their use for
bone marrow…
Webinar last updated
.
Node ID (debugging only): 685
Iptacopan (LNP023)
Iptacopan (LNP023):
Iptacopan (LNP023) is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway. It is currently in clinical development for treating PNH.
is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway. It is currently…
Drug last updated
.
Node ID (debugging only): 955
Tamibarotene
Tamibarotene:
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) .
(brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed…
Drug last updated
.
Node ID (debugging only): 947
Ravulizumab-cwvz
Ravulizumab-cwvz:
Ravulizumab-cwvz (Ultomiris®) is a drug approved by the U.S. Food and Drug Administration (FDA) in 2018 to treat PNH. ULTOMIRIS® is a long-acting C5 inhibitor that works by inhibiting the C5 protein in the terminal complement cascade. ULTOMIRIS® is a prescription medicine called a…
(Ultomiris®) is a drug approved by the U.S. Food…
Drug last updated
.
Node ID (debugging only): 941
Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.
Drug last updated
.
Node ID (debugging only): 951